Search research articles
Contact Us
Filters
Showing results (141-150 of 146) with videos related to
Page
of 15
Sort By:
You have reached the last page of results.
This site can display upto 146 results.
Cells
|
August 25, 2019
Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection
Sodsai Tovanabutra, Rujipas Sirijatuphat, Phuc T Pham, et al.
Nature Medicine
|
April 3, 2020
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption
Donn J Colby, Michal Sarnecki, Dan H Barouch, et al.
The Journal of Clinical Investigation
|
March 18, 2020
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
Evan M Cale, Hongjun Bai, Meera Bose, et al.
The Lancet. HIV
|
February 26, 2026
Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials
Thumbi Ndung'u, Krista L Dong, Donn J Colby, et al.
The Lancet. HIV
|
April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
Trevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
The Lancet. HIV
|
March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting
Boris Julg, Lynda Dee, Jintanat Ananworanich, et al.
Page
of 15
Search research articles
Search
Showing results (141-150 of 146) with videos related to
Sort By:
Page
of 15
You have reached the last page of results.
This site can display upto 146 results.
Cells
|
August 25, 2019
Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection
Sodsai Tovanabutra, Rujipas Sirijatuphat, Phuc T Pham, et al.
Nature Medicine
|
April 3, 2020
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption
Donn J Colby, Michal Sarnecki, Dan H Barouch, et al.
The Journal of Clinical Investigation
|
March 18, 2020
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
Evan M Cale, Hongjun Bai, Meera Bose, et al.
The Lancet. HIV
|
February 26, 2026
Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials
Thumbi Ndung'u, Krista L Dong, Donn J Colby, et al.
The Lancet. HIV
|
April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
Trevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
The Lancet. HIV
|
March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting
Boris Julg, Lynda Dee, Jintanat Ananworanich, et al.
Page
of 15